Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
French drug major Sanofi has announced top-line results from its Phase IIIb ELIXA study, comparing Lyxumia (lixisenatide) to placebo in a high-risk population of adults with type 2 diabetes. 19 March 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk says that the European Commission has approved the expanded use of Tresiba (insulin degludec) for children and adolescents with diabetes aged one to 17 years. 12 March 2015
Pharmaceutical
Japan’s largest drugmaker Takeda has published post-hoc analysis of data from the global EXAMINE trial showing that in patients with type 2 diabetes and recent acute coronary syndrome, alogliptin compared to placebo did not increase the risk of heart failure. 10 March 2015
Pharmaceutical
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a new dossier assessment whether vildagliptin offers an added benefit over the appropriate comparator therapy. 9 March 2015
Pharmaceutical
New data from Danish insulin giant Novo Nordisk has shown that adults with obesity or who are overweight with co-morbidities losing at least 5% body weight with Saxenda (liragultide) improved blood glucose, cardiovascular risk factors and quality of life outcomes. 9 March 2015
Biotechnology
US biotech firm Islet Sciences has entered into a license agreement with Brighthaven Ventures (BHV) for exclusive rights to develop and commercialize SGLT2 inhibitor remogliflozin etabonate. 3 March 2015
Pharmaceutical
The US Food and Drug Administration has approved French pharma major Sanofi’s Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. 26 February 2015
Pharmaceutical
US pharma major Eli Lilly says it is delaying the submission of its basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015. 23 February 2015
Pharmaceutical
Shares of Danish diabetes care giant Novo Nordisk jumped 5% to 312.20 Danish kroner in early afternoon trading, after the company released positive results from a Phase II trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes. 20 February 2015
Pharmaceutical
New Zealand’s Pharmaceutical Management Agency, PHARMAC, today revealed it is interested in receiving information from suppliers, clinicians and diabetes health care professionals in respect of the following classes of anti-diabetic agents. 12 February 2015
Pharmaceutical
Danish insulin giant Novo Nordisk is to join forces with Swedish researchers Karolinska Institutet for diabetes research. 10 February 2015
Pharmaceutical
Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has announced its latest findings regarding added benefit of Triumeq (dolutegravir/abacavir/lamivudine), a treatment for HIV from ViiV Healthcare, and GlaxoSmithKline's diabetes drug Eperzan (albiglutide), coming to mostly favorable conclusions. 5 February 2015
Pharmaceutical
US drugmaker Isis Pharmaceuticals has announced top-line results from a Phase II study of ISIS-PTP1BRx in patients with type 2 diabetes. The results show that the drug took longer than expected to work. The company's stock fell nearly 10% on Tuesday. 4 February 2015
Pharmaceutical
The only inhaled insulin Afrezza (human insulin) Inhalation Powder, developed by French drug major Sanofi and US biopharma company MannKind, is now available in the USA. 3 February 2015
Pharmaceutical
The US Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets from German family-owned drug major Boehringer Ingelheim and Eli Lilly to improve glycemic control in adults with type 2 diabetes. 2 February 2015
Biotechnology
USA-based BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle, have announced the formation of OptiKira. 2 February 2015
Pharmaceutical
Germany’s Merck KGaA has transferred responsibility for its diabetes and thyroid portfolio from marketing partner Takeda to Merck Serono in Russia. 2 February 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk posted financials this morning, showing that sales for full-year 2014 increased by 8% in local currencies to 88.8 billion Danish kroner ($13.42 billion; +6% in kroner). 30 January 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk revealed yesterday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Saxenda (liraglutide 3mg) for the treatment of obesity. 23 January 2015
Pharmaceutical
England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has issued further draft guidance which recommends Jardiance (empagliflozin), marketed by German family-owned pharma major Boehringer Ingelheim, for treating type 2 diabetes. 22 January 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze